

## Glioma

Recurrent

**BRN0064**  
Phase I Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAD-S-pk7) Administered Intracerebrally to Recurrent High Grade Gliomas  
PI: Hayden Gephart  
Sponsor: City of Hope

High Grade

Pre- Avastin

BRAF Mutation

IDH Mutant

FGFR1-3 Alteration

Surgical Procedural Candidates

None at this time

**BRN0048**  
[Phase I, First-In-Human Multicenter Open-Label Study of ABM-1310, Administered Orally in Adult Patients with Advanced Solid Tumors](#)  
PI: Nagpal  
Sponsor: ABM Therapeutics, Inc.

**BRN0061**  
Phase II Multicenter Open Label Two Parts Clinical Study to Evaluate Efficacy & Safety of Safusidenib Erbumine in Isocitrate Dehydrogenase 1 (IDH1) Mutant Glioma  
PI: Nagpal  
Sponsor: AnHeart Therapeutics Inc.

**BRNCNS0009**  
[Phase I/II Open-Label Study Evaluating Efficacy & Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms during Neurosurgical Procedures](#)  
PI: Li  
Sponsor: Stanford University

**BRN0056**  
[Phase I/II Dose-Escalation Study of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects](#)  
PI: Nagpal  
Sponsor: VBI Vaccines Inc.

**BRN0057**  
Open Label Prospective Pilot Study to Evaluate the Safety & Effectiveness of the NaviFUS System in Conjunction w/ a Standard Treatment Regimen of Bevacizumab (BEV) in Recurrent Glioblastoma  
PI: Airan  
Sponsor: NaviFUS US LLC

**BRN0042**  
Phase II/III Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM  
PI: Recht  
Sponsor: Global Coalition for Adaptive Research

**BRN0064**  
Phase I Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAD-S-pk7) Administered Intracerebrally to Recurrent High Grade Gliomas  
PI: Hayden Gephart  
Sponsor: City of Hope

**CCT5061**  
[Phase I Loco-regionally \(LR\) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells \(B7-H3CART\) in Recurrent Glioblastoma Multiforme \(GBM\)](#)  
PI: Thomas  
Sponsor: Stanford University  
Priority 1

**BRN0045**  
[Phase I/II Exablate Type 2 for BBBD With Microbubble Resonators in Tx of rGBM in Carboplatin Mono Treatment](#)  
PI: Nagpal  
Sponsor: InSightec, Inc.

**BRN0049**  
[Phase Ib Eval Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 \(Nivolumab\) or the Combo of Anti-PD-1 + Anti-CTLA-4 \(Ipilimumab\) in Surgically Accessible Glioblastoma](#)  
PI: Lim  
Sponsor: Dana Farber Cancer Institute  
Priority 3

**BRN0062**  
Randomized Surgical Window of Opportunity Study w/ Dose Escalation to Evaluate Whether Oral Fluoxetine Can Induce Cytotoxic Lysosomal Stress & Enhance Temozolomide Efficacy in Clinical Glioma (The FLIT Trial)  
PI: Nagpal  
Sponsor: Duke Cancer Institute  
Priority 2

**VAR0250**  
Phase I Open-Label Multi-Center Study to Evaluate the Safety Tolerability Dosimetry & Preliminary Activity of [177Lu]Lu-FF58 in Selected Advanced Solid Tumors  
PI: Igaru  
Sponsor: Novartis Pharmaceuticals Corporation

**KE**

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy